Safety and efficacy findings from the open-label, multicenter, phase 3b Par MarcGuevreguian|2021-03-23T09:54:43+01:00juillet 30th, 2019| Lire la suite
Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia Par MarcGuevreguian|2021-03-23T10:22:16+01:00juillet 26th, 2019| Lire la suite
Checkpoint inhibitor treatment induces an increase in HbA1c in nondiabetic patients Par MarcGuevreguian|2021-03-23T11:12:47+01:00juin 29th, 2019| Lire la suite
IPH4102, a first-in-class anti-KIR3DL2 monoclonal antibody… Par MarcGuevreguian|2021-03-23T10:16:25+01:00juin 25th, 2019| Lire la suite
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma Par MarcGuevreguian|2021-03-23T11:10:41+01:00juin 4th, 2019| Lire la suite
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma Par MarcGuevreguian|2021-03-23T11:23:36+01:00mai 30th, 2019| Lire la suite
Emerging translational science discoveries, clonal approaches, and treatment trends… Par MarcGuevreguian|2021-03-23T09:58:52+01:00avril 23rd, 2019| Lire la suite
A Constitutional Activating MET Mutation Makes the Genetic Link between Malignancies and Chronic Inflammatory Diseases Par MarcGuevreguian|2021-03-23T10:06:56+01:00avril 19th, 2019| Lire la suite
Thromboembolic events in polycythemia vera Par MarcGuevreguian|2021-03-23T10:04:54+01:00mars 8th, 2019| Lire la suite
Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab… Par MarcGuevreguian|2021-03-23T11:15:07+01:00février 27th, 2019| Lire la suite
